1,2,3,4-四氢异喹啉-3-羧酸乙酯 | 41234-43-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1,2,3,4-四氢异喹啉-3-羧酸乙酯
• 中文别名: 乙基1,2,3,4-四氢异喹啉-3-甲酸酯；1,2,3,4-四氢异喹啉-3-甲酸乙酯
• 英文名称: ethyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate
• 英文别名: ethyl 1,2,3,4-tetrahydroisoquinoline-3-(S)-carboxylate
• CAS: 41234-43-9
• 化学式: C₁₂H₁₅NO₂
• 分子量: 205.257
• InChiKey: RGHMPTHWVVRXHW-UHFFFAOYSA-N

物化性质

• 熔点：
  204℃
• 沸点：
  120 °C(Press: 1 Torr)
• 密度：
  1.101±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢异喹啉-3-羧酸乙酯 在 三乙胺 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 2-(naphthalene-1-carbonyl)-N-phenyl-3,4-dihydro-1H-isoquinoline-3-carboxamide
  参考文献：
  名称：

  Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonists

  摘要：

  The design and synthesis of a novel series of Rev-erb alpha agonists is described. The development and optimization of the tetrahydroisoquinoline series was carried out from an earlier acyclic series of Rev-erb alpha agonists. Through the optimization of the scaffold 1, several potent compounds with good in vivo profiles were discovered. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.023
• 作为产物：
  描述：

  1,2,3, 4-tetrahydroisoquinoline-3-carboxylic acid camphor sulphonic acid salt 在 crude residue 、 二氯甲烷 、 碳酸氢钠 、 Sodium sulfate-III 作用下， 以 乙醇 、 盐酸 为溶剂， 反应 18.0h， 以to give the title compound as a yellow oil (3.64 g, 100%)的产率得到1,2,3,4-四氢异喹啉-3-羧酸乙酯
  参考文献：
  名称：

  Antiparasitic terpene alkaloids

  摘要：

  本发明涉及新型萜类生物碱及其作为抗寄生虫剂的用途。本发明还涉及一种抗寄生虫剂，其包含本发明中的萜类生物碱化合物作为抗寄生虫制剂中的有效成分。更具体地，本发明涉及萜类生物碱（1S，2R，4aS，5R，8R，8aR）-2-（乙酰氧基）-8a-羟基-3，8-二甲基-5-（1-甲基乙烯基）-1,2,4a,5,6,7,8,8a-八氢萘-1-基（2S，3aR，9bR）-6-氯-9b-羟基-5-甲基-1,2,3,3a,5,9b-六氢吡咯[2,3-c] [2,1]苯并噁唑-2-羧酸酯的衍生物。还公开了包含该物质的药物组合物。

  公开号：

  US20070185101A1

文献信息

• [EN] CXCR3 RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR CXCR3
  申请人：CELGENE INT II SARL

  公开号：WO2018045246A1

  公开（公告）日：2018-03-08

  Compounds are provided having the structure of the following Formula I: where R, R1, R2, R3a and R3b are as defined herein. Pharmaceutical compositions comprising such compounds, as well as methods related to their manufacture and use, are also provided.

  提供具有以下式I结构的化合物：其中R、R1、R2、R3a和R3b如本文所述定义。还提供了包含这些化合物的药物组合物，以及与它们的制造和使用相关的方法。
• [EN] MODULATORS OF REV-ERB<br/>[FR] MODULATEURS DE REV-ERB
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015103527A1

  公开（公告）日：2015-07-09

  The subject matter herein concerns the identification and development of potent synthetic REV-ERB ligands, such as in vivo agonists and antagonists. These compounds allow for characterization of the effects of modulation of this receptor in vivo specifically on circadian behavior and metabolism, and have suitable characteristics for development of medicinal compounds useful for treatment of malconditions such as diabetes, obesity, atherosclerosis, dyslipidemia, a circadian rhythm disorder, coronary artery disease, bipolar disorder, depression, cancer, a sleep disorder, an anxiety disorder, an addiction disorder, a bone-related disorder such osteoporosis, a skeletal muscle disease, e.g., with compromised exercise capacity, or an autoimmune disorder such as psoriasis, multiple sclerosis, inflammatory bowel disease, and others.

  本文涉及识别和开发强效合成REV-ERB配体，例如体内激动剂和拮抗剂。这些化合物可用于特定在体内对昼夜节律行为和新陈代谢的调节效果进行表征，并具有适合开发用于治疗糖尿病、肥胖症、动脉粥样硬化、血脂异常、昼夜节律紊乱、冠状动脉疾病、躁郁症、抑郁症、癌症、睡眠障碍、焦虑障碍、成瘾障碍、骨相关疾病如骨质疏松症、骨骼肌肉疾病（例如，运动能力受损）、自身免疫性疾病如牛皮癣、多发性硬化、炎症性肠病等疾病的药用化合物的特性。
• [EN] PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV<br/>[FR] COMPOSES PYRIDINES UTILISES COMME INHIBITEURS DE DIPEPTIDYLE PEPTIDASE IV
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005042488A1

  公开（公告）日：2005-05-12

  A compound represented by the formula wherein R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; R3 is an optionally substituted aromatic group; R4 is an optionally substituted amino group; L is a divalent chain hydrocarbon group; Q is a bond or a divalent chain hydrocarbon group; and X is a hydrogen atom, a cyano group, a nitro group, an acyl group, a substituted hydroxy group, an optionally substituted thiol group, an optionally substituted amino group or an optionally substituted cyclic group; provided that when X is an ethoxycarbonyl group, then Q is a divalent chain hydrocarbon group. The compound has a peptidase inhibitory action, is useful as an agent for the prophylaxis or treatment of diabetes and the like, and is superior in efficacy, duration of action, specificity, lower toxicity and the like.

  该化合物的化学式表示为其中R1和R2相同或不同，每个都是可选择取代的碳氢基团或可选择取代的羟基团；R3是可选择取代的芳香基团；R4是可选择取代的氨基团；L是二价链状碳氢基团；Q是键或二价链状碳氢基团；X是氢原子、氰基、硝基、酰基、取代的羟基团、可选择取代的硫醇基团、可选择取代的氨基团或可选择取代的环状基团；但当X是乙氧羰基团时，Q为二价链状碳氢基团。该化合物具有肽酶抑制作用，可用作糖尿病等疾病的预防或治疗药物，并在功效、作用持续时间、特异性、毒性较低等方面具有优越性。
• Tetrahydroisoquinolinealkanol derivatives and pharmaceutical
  申请人：SK Corporation

  公开号：US05955471A1

  公开（公告）日：1999-09-21

  The present invention provides novel 1,2,3,4-tetrahydroisoquinoline carbamate and thiocarbamate derivatives represented by Formula I ##STR1## wherein: X.sub.1 and X.sub.2 are the same or different from each other and independently represent a a member selected from the group consisting of hydrogen, alkyl, alkoxy, thioalkoxy, halogen, hydroxy, nitro and trifluorocarbon; Y is a member selected from the group consisting of oxygen and sulfur; R.sub.1 is a member selected from the group consisting of hydrogen, alkyl, arylalkyl, and CONHR' where R' is selected from the group consisting of hydrogen, alkyl, arylalkyl and aryl; R.sub.2 and R.sub.3 are the same or different from each other and independently represent a member selected from the group consisting of hydrogen, alkyl, arylalkyl, and cycloalkyl, or R.sub.2 and R.sub.3 may form a 5 to 7-membered ring together with the nitrogen atom to which they are bonded; R.sub.4 is a member selected from the group consisting of hydrogen or lower alkyl; and nontoxic pharmacologically acceptable salts thereof. Compounds are useful in the treatment of central nervous system disorders, including depression.

  本发明提供了新颖的1,2,3,4-四氢异喹啉氨基甲酸酯和硫代氨基甲酸酯衍生物，其结构如式I所示 ##STR1## 其中：X1和X2彼此相同或不同，独立地表示氢、烷基、烷氧基、硫代烷氧基、卤素、羟基、硝基和三氟甲基中的一种；Y表示氧或硫；R1表示氢、烷基、芳基烷基和CONHR'中的一种，其中R'表示氢、烷基、芳基烷基和芳基中的一种；R2和R3彼此相同或不同，独立地表示氢、烷基、芳基烷基和环烷基中的一种，或者R2和R3可以与它们所连接的氮原子一起形成5至7元环；R4表示氢或低级烷基；以及其无毒的药理学上可接受的盐。这些化合物可用于治疗中枢神经系统疾病，包括抑郁症。
• Thrombin inhibitors. 3. Carboxyl-containing amide derivatives of N.alpha.-substituted L-arginine
  作者：Ryoji Kikumoto、Yoshikuni Tamao、Kazuo Ohkubo、Tohru Tezuka、Shinji Tonomura、Shosuke Okamoto、Akiko Hijikata

  DOI：10.1021/jm00186a003

  日期：1980.12

  N alpha-(arylsulfonyl)-L-arginine amide derivatives having carboxamide N-substituents with a carboxyl group was prepared and tested as inhibitors of the clotting activity of thrombin. The most inhibitory compounds were obtained when a carboxyl group was introduced into the carbon next to the amide nitrogen of N alpha-(arylsulfonyl)-L-arginine amide derivatives, e.g., N alpha-(arylsulfonyl)-L-arginyl-N-butyl-

  制备了一系列具有羧基羧基酰胺N-取代基的Nα-（芳基磺酰基）-L-精氨酸酰胺衍生物，并测试了它们作为凝血酶凝血活性的抑制剂。当在Nα-（芳基磺酰基）-L-精氨酸酰胺衍生物（例如Nα-（芳基磺酰基）-L-精氨酸-N-丁基）的酰胺氮旁的碳原子中引入羧基时，获得最具抑制性的化合物。 -，N-（甲氧基乙基）-或N-（四氢糠基）甘氨酸和4-烷基-1- [Nα-（芳基磺酰基）-L-精氨酰基] -2-哌啶甲酸，I50为1-3 X 10（ -7）M.